Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bernard Masson is active.

Publication


Featured researches published by Bernard Masson.


Archives of Surgery | 2008

A Single-Institution Prospective Study of Laparoscopic Pancreatic Resection

Antonio Sa Cunha; A. Rault; Cedric Beau; C. Laurent; Denis Collet; Bernard Masson

HYPOTHESIS Laparoscopic pancreatic resection can safely duplicate all of the open pancreatic procedures. DESIGN A prospective evaluation of laparoscopic pancreatic resection. Surgical procedure, postoperative course, and follow-up data were collected. SETTING Department of Abdominal Surgery at Haut-Lévêque Hospital, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France. PATIENTS Sixty patients with presumed pancreatic neoplasms. Final diagnoses were benign disease in 57 patients (95%) and malignant pancreatic disease in 3 patients (5%). MAIN OUTCOME MEASURES Complication and success rates of resections. RESULTS Twenty percent of procedures were switched to open laparotomy. Laparoscopically successful procedures included 20 distal pancreatectomies with spleen preservation, 5 distal splenopancreatectomies, 16 enucleations, 5 medial pancreatectomies, 1 pancreatoduodenectomy, and 1 total pancreatectomy. Postoperative death occurred in 1 patient (1.6%). The overall postoperative complication rate was 36%, including a 13% rate of clinical fistulae. In successful laparoscopic operations, the mean (SD) postoperative hospital stay was 12.7 (6) days. Multivariate, stepwise analysis identified pancreatic consistency and pancreatic resection that required anastomosis as independent factors of postoperative complication (P = .02 and P = .002, respectively). The 3 patients operated on for pancreatic malignancies were still alive at follow-up (median, 23 months); all patients with benign disease were alive at long-term follow-up. CONCLUSIONS This series demonstrates that laparoscopic pancreatic resection is not only feasible but also safe. Our study suggests that the best indications for a laparoscopic approach are presumably benign pancreatic tumors not requiring pancreaticoenteric reconstruction.


Gastroenterologie Clinique Et Biologique | 2006

Subsequent resection of locally advanced pancreatic carcinoma after chemoradiotherapy.

X. Adhoute; D. Smith; V. Vendrely; A. Rault; Antonio Sa Cunha; Jean-Louis Legoux; Geneviève Belleannée; Victor de Ledinghen; Patrice Couzigou; Bernard Masson

OBJECTIVES The aim of this study was to evaluate the possibility of subsequent resection of locally advanced pancreatic adenocarcinoma after chemotherapy and external-beam radiotherapy. PATIENTS AND METHODS Between January 1996 and January 2001, 33 consecutive patients (18 males and 15 women, mean age 63 years) with locally advanced PA were treated with chemotherapy and concurrent external-beam radiotherapy. Radiotherapy delivered 45-50.4 Gy, in a classical manner (N=27) or on a split-course (N=6). Chemotherapy was made of 5FU by continuous infusion for all patients during 5 weeks and cisplatin at the 1st and 5th weeks (N=22). Tumor resectability was reassessed at the end of the chemoradiotherapy; surgical resection of tumour was attempted in patients whose tumor demonstrated reduction in size, and supplementary radiotherapy of 10 to 15 Gy was delivered to the others. RESULTS Thirty-nine percent of patients experienced grade 3 acute toxicity. WHO criteria response to chemoradiotherapy four weeks after the end of treatment were: 4 partial responders (12%), 6 minor responders (18%), 14 stable disease (42%), 9 progression (28%). Ten patients underwent exploratory laparotomy, in one case vascular encasement did not allow for tumor resection, and in another patient, there was peritoneal carcinomatosis. In the 8 remaining patients, surgical (R0) resection was possible. In one patient histological examination showed fibrosis with no residual tumour. After a median follow-up period of 40 months, median survival was 16 months (66% and 37% of survival at 1 and 2 years respectively). In operated and non-operated patients, survival rates at 24 months were 73% and 12.5% respectively. At 1 year, 80% of the patients treated with radiochemotherapy developed recurrence, metastatic recurrence in 88%. Initial laparotomy, split course radiotherapy were poor outcome factors whereas chemotherapy appears to be a favorable outcome factor. CONCLUSION Subsequent resection of locally advanced pancreatic adenocarcinoma is possible after chemoradiotherapy allowing for a prolonged survival in some patients.


Hpb | 2012

Wirsungostomy as a salvage procedure after pancreaticoduodenectomy

Quentin Denost; Arnaud Pontallier; A. Rault; Jacques Ewald; D. Collet; Bernard Masson; Antonio Sa-Cunha

BACKGROUND   Mortality rates associated with postoperative peritonitis or haemorrhage secondary to pancreatic fistula (PF) after pancreaticoduodenectomy (PD) remain high. This study analysed the results of an alternative management strategy for these life-threatening complications. METHODS   All patients undergoing PD between January 2004 and April 2011 were identified. Patients who underwent further laparotomy for failure of the pancreatico-digestive anastomosis were identified. Since 2004, this problem has been managed by dismantling the pancreatico-digestive anastomosis and cannulating the pancreatic duct remnant with a thin polyethylene tube (Escat tube), which is then passed through the abdominal wall. Main outcome measures were mortality, morbidity and longterm outcome. RESULTS   From January 2004 to April 2011, 244 patients underwent a PD. Postoperatively, 21 (8.6%) patients required re-laparotomy to facilitate a wirsungostomy. Two patients were transferred from another hospital with life-threatening PF after PD. Causes of re-laparotomy were haemorrhage (n= 12), peritonitis (n= 4), septic shock (n= 4) and mesenteric ischaemia (n= 1). Of the 21 patients who underwent wirsungostomy, six patients subsequently died of liver failure (n= 3), refractory septic shock (n= 2) or mesenteric ischaemia (n= 1) and nine patients suffered complications. The median length of hospital stay was 42 days (range: 34-60 days). The polyethylene tube at the pancreatic duct was removed at a median of 4 months (range: 2-11 months). Three patients developed diabetes mellitus during follow-up. CONCLUSIONS   These data suggest that preservation of the pancreatic remnant with wirsungostomy has a role in the management of patients with uncontrolled haemorrhage or peritonitis after PF.


Journal of The American College of Surgeons | 2005

Pancreaticojejunal Anastomosis Is Preferable to Pancreaticogastrostomy after Pancreaticoduodenectomy for Longterm Outcomes of Pancreatic Exocrine Function

A. Rault; Antonio Sa-Cunha; Daniel Klopfenstein; D. Larroudé; Frédéric N. Dobo Epoy; Denis Collet; Bernard Masson


Journal of The American College of Surgeons | 2005

Surgical Resection after Radiochemotherapy in Patients with Unresectable Adenocarcinoma of the Pancreas

Antonio Sa Cunha; A. Rault; Christophe Laurent; X. Adhoute; V. Vendrely; Geneviève Béllannée; René Brunet; Denis Collet; Bernard Masson


Surgery | 2007

Laparoscopic central pancreatectomy : Single institution experience of 6 patients

Antonio Sa Cunha; A. Rault; Cedric Beau; Denis Collet; Bernard Masson


JAMA Surgery | 2013

Laparoscopic Spleen-Preserving Distal Pancreatectomy: Splenic Vessel Preservation Compared With the Warshaw Technique

Jean-Philippe Adam; Alexandre Jacquin; Christophe Laurent; Denis Collet; Bernard Masson; Laureano Fernández-Cruz; Antonio Sa-Cunha


/data/revues/03998320/00300002/224/ | 2008

Subsequent resection of locally advanced pancreatic carcinoma after chemoradiotherapy

X. Adhoute; Denis Smith; V. Vendrely; Alexandre Rault; Antonio Sa Cunha; Jean-Louis Legoux; Geneviève Belleannée; Victor de Ledinghen; Patrice Couzigou; Bernard Masson


Pancreas | 2009

Acute recurrent pancreatitis by heterotopic fundic mucosa at the ampulla of vater.

Julien Jarry; A. Rault; Antonio Sa Cuhna; Denis Collet; Bernard Masson


Hépato-Gastro & Oncologie Digestive | 2009

Peut-on rendre résécable un cancer du pancréas non (ou difficilement) résécable ?

Antonio Sa Cunha; Bernard Masson

Collaboration


Dive into the Bernard Masson's collaboration.

Top Co-Authors

Avatar

A. Rault

University of Bordeaux

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

V. Vendrely

University of Bordeaux

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

D. Collet

University of Bordeaux

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

D. Smith

University of Bordeaux

View shared research outputs
Researchain Logo
Decentralizing Knowledge